Background: Cryptosporidium species are pathogenic intestinal protozoa that contribute to significant morbidity and mortality rates. Our study aim was to study the effectiveness of rosuvastatin (crestor) on treatment of cryptosporidiosis as an attempt to overcome shortcomings of other traditional drugs to decrease the incidence of cryptosporidiosis.
Methods: This experimental interventional trial that was done on 50 laboratory-bred male Swiss albino mice at Parasitology and Zoonotic Diseases Department, Faculty of Medicine, Benha University and Zoonotic Diseases Department, Theodor Bilharz Research Institute, Cairo, Egypt. Animals were distributed into 5 groups: Group A: Non infected non treated (control negative), Group B: Infected untreated (control positive), Group C: Infected treated with nitazoxanide (nanazoxide) 500mg/kg once daily for 1week, Group D: Infected treated with rosuvastatin (crestor) 20 mg/kg once every day for 1week and Group E: Infected treated with nitazoxanide (nanazoxide) 250 mg/kg once every day and with rosuvastatin (crestor) 10 mg/kg once every day for 1week.